IM Cannabis Past Earnings Performance
Past criteria checks 0/6
IM Cannabis's earnings have been declining at an average annual rate of -13.2%, while the Pharmaceuticals industry saw earnings declining at 0.3% annually. Revenues have been growing at an average rate of 34.7% per year.
Key information
-13.2%
Earnings growth rate
6.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 34.7% |
| Return on equity | -276.1% |
| Net Margin | -28.2% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
IM Cannabis Shareholder Rafael Gabay raises stake
Sep 08IM Cannabis GAAP EPS of -C$0.30, revenue of C$23.8M
Aug 15IM Cannabis receives non-compliance notification from Nasdaq for minimum bid price requirement
Jul 19cbdMD And IM Cannabis Partner To Sell CBD Products In Israeli Markets
Aug 14IM Cannabis proposes public offering of securities
May 05IM Cannabis acquires Israel's largest retail and online pharmacy business from Panaxia
Apr 30Revenue & Expenses Breakdown
How IM Cannabis makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 50 | -14 | 19 | 0 |
| 31 Mar 24 | 48 | -15 | 20 | 0 |
| 31 Dec 23 | 49 | -9 | 22 | 0 |
| 30 Sep 23 | 53 | -15 | 18 | 0 |
| 30 Jun 23 | 54 | -17 | 21 | 0 |
| 31 Mar 23 | 54 | -17 | 23 | 0 |
| 31 Dec 22 | 54 | -23 | 24 | 0 |
| 30 Sep 22 | 50 | -22 | 32 | 0 |
| 30 Jun 22 | 44 | -16 | 32 | 0 |
| 31 Mar 22 | 38 | -10 | 30 | 0 |
| 31 Dec 21 | 34 | 0 | 29 | 0 |
| 30 Sep 21 | 29 | -10 | 27 | 0 |
| 30 Jun 21 | 27 | -12 | 23 | 0 |
| 31 Mar 21 | 23 | -24 | 23 | 0 |
| 31 Dec 20 | 16 | -29 | 19 | 0 |
| 30 Sep 20 | 13 | -7 | 14 | 0 |
| 30 Jun 20 | 10 | -10 | 13 | 0 |
| 31 Mar 20 | 8 | -1 | 11 | 0 |
| 31 Dec 19 | 9 | -7 | 10 | 0 |
| 30 Sep 19 | 8 | -8 | 9 | 0 |
| 30 Jun 19 | 7 | -6 | 7 | 0 |
| 31 Mar 19 | 6 | -6 | 5 | 0 |
| 31 Dec 18 | 5 | 2 | 3 | 0 |
| 31 Dec 17 | 4 | 1 | 2 | 0 |
Quality Earnings: IMCC is currently unprofitable.
Growing Profit Margin: IMCC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IMCC is unprofitable, and losses have increased over the past 5 years at a rate of 13.2% per year.
Accelerating Growth: Unable to compare IMCC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IMCC is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (13%).
Return on Equity
High ROE: IMCC has a negative Return on Equity (-276.08%), as it is currently unprofitable.